Marriott's strategic initiatives, like the MGM Collection partnership, propelled its global room count. While first-quarter results slightly missed expectations, the company's optimistic outlook and raised adjusted EPS guidance for FY24 underscore confidence in its ability to navigate challenges and deliver shareholder value.
The agency noted that in 2023, half of the new type 2 diabetes patients started their treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first.
Pfizer reports Q1 results: adjusted EPS beats estimates, driven by revenue growth. Significant declines in Comirnaty and Paxlovid revenues countered by operational gains. Company announces plans for direct-to-consumer online platform.
Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix. Expectations soar with raised 2024 EPS and sales forecasts.